WALTHAM, Mass, – August 4, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU) today announced it has filed a Form 25 with the Securities and Exchange Commission in furtherance of its plan to delist and deregister its securities in order to obtain relief from its reporting obligations under the Exchange Act and preserve capital for shareholders and the satisfaction of debtors.

The Company announced on July 25, 2017, that it would begin the process of delisting and deregistering its securities.  The Company intends to file a Form 15 with the Securities and Exchange Commission on or about August 14, 2017 in order to complete the delisting and deregistration process commonly referred to as “going dark.”

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics’ lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA™ Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.